These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35204129)

  • 1. Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson's Disease.
    Duarte P; Michalska P; Crisman E; Cuadrado A; León R
    Antioxidants (Basel); 2022 Jan; 11(2):. PubMed ID: 35204129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melatonin Analogues Potently Inhibit MAO-B and Protect PC12 Cells against Oxidative Stress.
    Elkamhawy A; Woo J; Gouda NA; Kim J; Nada H; Roh EJ; Park KD; Cho J; Lee K
    Antioxidants (Basel); 2021 Oct; 10(10):. PubMed ID: 34679739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation.
    Anastassova N; Aluani D; Kostadinov A; Rangelov M; Todorova N; Hristova-Avakumova N; Argirova M; Lumov N; Kondeva-Burdina M; Tzankova V; Yancheva D
    Neural Regen Res; 2021 Nov; 16(11):2299-2309. PubMed ID: 33818516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Potent, Selective, and Competitive Indole-Based MAO-B Inhibitors Protect PC12 Cells against 6-Hydroxydopamine- and Rotenone-Induced Oxidative Stress.
    Elsherbeny MH; Kim J; Gouda NA; Gotina L; Cho J; Pae AN; Lee K; Park KD; Elkamhawy A; Roh EJ
    Antioxidants (Basel); 2021 Oct; 10(10):. PubMed ID: 34679775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action.
    Elkamhawy A; Kim HJ; Elsherbeny MH; Paik S; Park JH; Gotina L; Abdellattif MH; Gouda NA; Cho J; Lee K; Nim Pae A; Park KD; Roh EJ
    Bioorg Chem; 2021 Nov; 116():105352. PubMed ID: 34562673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.
    Bar-Am O; Amit T; Kupershmidt L; Aluf Y; Mechlovich D; Kabha H; Danovitch L; Zurawski VR; Youdim MB; Weinreb O
    Neurobiol Aging; 2015 Mar; 36(3):1529-42. PubMed ID: 25499799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double Attack to Oxidative Stress in Neurodegenerative Disorders: MAO-B and Nrf2 as Elected Targets.
    Basagni F; Di Paolo ML; Cozza G; Dalla Via L; Fagiani F; Lanni C; Rosini M; Minarini A
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Curcumin-Diethyl Fumarate Hybrid as a Dualistic GSK-3β Inhibitor/Nrf2 Inducer for the Treatment of Parkinson's Disease.
    Di Martino RMC; Pruccoli L; Bisi A; Gobbi S; Rampa A; Martinez A; Pérez C; Martinez-Gonzalez L; Paglione M; Di Schiavi E; Seghetti F; Tarozzi A; Belluti F
    ACS Chem Neurosci; 2020 Sep; 11(17):2728-2740. PubMed ID: 32663009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
    Liu Z; Cai W; Lang M; Yan R; Li Z; Zhang G; Yu P; Wang Y; Sun Y; Zhang Z
    J Mol Neurosci; 2017 Apr; 61(4):498-510. PubMed ID: 28144826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease.
    Nam MH; Park M; Park H; Kim Y; Yoon S; Sawant VS; Choi JW; Park JH; Park KD; Min SJ; Lee CJ; Choo H
    ACS Chem Neurosci; 2017 Jul; 8(7):1519-1529. PubMed ID: 28332824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ellagic acid exerts protective effect in intrastriatal 6-hydroxydopamine rat model of Parkinson's disease: Possible involvement of ERβ/Nrf2/HO-1 signaling.
    Baluchnejadmojarad T; Rabiee N; Zabihnejad S; Roghani M
    Brain Res; 2017 May; 1662():23-30. PubMed ID: 28238669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icariin attenuates neuroinflammation and exerts dopamine neuroprotection via an Nrf2-dependent manner.
    Zhang B; Wang G; He J; Yang Q; Li D; Li J; Zhang F
    J Neuroinflammation; 2019 Apr; 16(1):92. PubMed ID: 31010422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel indanone derivatives as MAO B/H
    Affini A; Hagenow S; Zivkovic A; Marco-Contelles J; Stark H
    Eur J Med Chem; 2018 Mar; 148():487-497. PubMed ID: 29477889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear factor erythroid 2-related factor 2 signaling in Parkinson disease: a promising multi therapeutic target against oxidative stress, neuroinflammation and cell death.
    Kumar H; Koppula S; Kim IS; More SV; Kim BW; Choi DK
    CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):1015-29. PubMed ID: 23244425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
    Gal S; Fridkin M; Amit T; Zheng H; Youdim MB
    J Neural Transm Suppl; 2006; (70):447-56. PubMed ID: 17017567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.
    Ahuja M; Ammal Kaidery N; Yang L; Calingasan N; Smirnova N; Gaisin A; Gaisina IN; Gazaryan I; Hushpulian DM; Kaddour-Djebbar I; Bollag WB; Morgan JC; Ratan RR; Starkov AA; Beal MF; Thomas B
    J Neurosci; 2016 Jun; 36(23):6332-51. PubMed ID: 27277809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.